Anders Rylander

Biovica develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and predict patient outcomes. The company’s DiviTum™ TKa assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.